Companies: 10,795·Total market cap: $144.5T
Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

AGIONASDAQHealthcare● Active
$27.44
$-0.85(-3.00%)
Market Cap$1.6B
P/E Ratio
52W High$46
52W Low$22.24
SEC Filings

Agios Pharmaceuticals, Inc. (AGIO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001439222 · AGIO · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
SCHEDULE 13G/A
Latest Form
2026-05-15
Most Recent
2013
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001439222 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-12
Fiscal Year End
Feb 12, 2026
Accession No.
0001439222-26-000025
Primary Document
agio-20251231.htm
Source: data.sec.gov · CIK 0001439222 · Accession 0001439222-26-000025

Latest Key Filings

10-QQuarterly Report
10-Q
2026-04-29
8-KCurrent Report
8-K
2026-04-29Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-06
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-29
View
10-QQuarterly Report
10-Q
2026-04-29
View
8-KCurrent Report
8-K
2026-04-29
View
ARSARS
ARS
2026-04-24
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-24
View
DEF 14AProxy Statement
DEF 14A
2026-04-24
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-17
View
S-3ASRS-3ASR
S-3ASR
2026-02-12
View
10-KAnnual Report
10-K
2026-02-12
View
8-KCurrent Report
8-K
2026-02-12
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-09
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-09
View
Showing 1–15 of 410 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001439222  |  Exchange: NASDAQ · Healthcare

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2013. As a Healthcare sector company with CIK 0001439222, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Agios Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Agios Pharmaceuticals, Inc. 10-K was filed on 2026-02-12 for fiscal year ending 2026. Historical AGIO 10-K annual reports are available from 2015 through 2026.

Investors researching Agios Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

AGIO SEC Filings · 8 questions

Agios Pharmaceuticals, Inc. (AGIO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Agios Pharmaceuticals, Inc.'s CIK is 0001439222.

AGIO SEC filingsAgios Pharmaceuticals, Inc. SEC documentsfind AGIO 10-K